Altimmune (ALT) | Stock Overview & Key Data
Altimmune Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: $137.70 on May 22, 2017
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Altimmune ALT | 345.52M Small-cap | -8.73% | -39.16% | -7.73% | -36.47% | -41.21% | -32.17% | -67.43% | -83.38% |
| Vertex VRTX | 120.40B Large-cap | -0.46% | 2.95% | -7.25% | 9.41% | 14.40% | -3.91% | 68.52% | 69.61% |
| Regeneron REGN | 61.30B Large-cap | 0.04% | 4.84% | -1.78% | -22.10% | -23.38% | -46.35% | -2.65% | -6.30% |
| Disc Medicine IRON | 2.00B Small-cap | 6.23% | 8.17% | 36.21% | -6.95% | -9.90% | 27.18% | 21.05% | -81.56% |
| Cg Oncology CGON | 1.97B Small-cap | -3.89% | -2.00% | 24.07% | -15.74% | -13.88% | -26.46% | -26.06% | -26.06% |
| Ideaya Biosciences IDYA | 1.97B Small-cap | -0.09% | -4.29% | 26.21% | -7.87% | -14.83% | -44.78% | 51.65% | 89.75% |
Ownership & Short Interest
Altimmune Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Altimmune would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
What is ALT's 52-week high and low?
In the last 52 weeks, Altimmune reached a high of $11.16 (on November 13, 2024) and a low of $2.90 (on June 26, 2025).
What is the market cap and P/E ratio for ALT?
Curious about Altimmune's size and valuation? Its market capitalization stands at 345.52M. When it comes to valuation, the P/E ratio (trailing twelve months) is -3.18, and the forward P/E (looking ahead) is -2.90.
Does ALT pay dividends? If so, what's the yield?
As for dividends, Altimmune isn't currently offering a significant yield, or that specific data isn't available right now.
Who are Altimmune's main competitors or similar companies to consider before investing?
When looking at Altimmune, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
| Company | Mkt Cap | Sector | Industry | 1Y Return | 3Y Return |
|---|---|---|---|---|---|
| Vertex VRTX | 120.40B | Healthcare | Biotechnology | -3.91% | 68.52% |
| Regeneron REGN | 61.30B | Healthcare | Biotechnology | -46.35% | -2.65% |
| Disc Medicine IRON | 2.00B | Healthcare | Biotechnology | 27.18% | 21.05% |
| Cg Oncology CGON | 1.97B | Healthcare | Biotechnology | -26.46% | -26.06% |
| Ideaya Biosciences IDYA | 1.97B | Healthcare | Biotechnology | -44.78% | 51.65% |
For a more comprehensive list, please see the Peer Performance Comparison table on this page.
What are the key financial health indicators for Altimmune, Inc.? (e.g., ROE, Debt/Equity)
To get a sense of Altimmune's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -57.28%, the Debt to Equity ratio from the most recent quarter is 1.12, and its Gross Profit Margin stands at N/A.
What is the recent revenue and earnings growth for ALT?
Looking at Altimmune's growth, its revenue over the trailing twelve months (TTM) was $20K. Compared to the same quarter last year (YoY), quarterly revenue grew by 0.00%, and quarterly earnings saw a YoY growth of 0.00%.
How much of ALT stock is held by insiders and institutions?
Wondering who owns Altimmune stock? Company insiders (like executives and directors) hold about 0.76% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 47.85%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.